|Bid||0.26 x 22255000|
|Ask||0.26 x 14894400|
|Day's range||0.26 - 0.26|
|52-week range||0.23 - 0.31|
|PE ratio (TTM)||N/A|
|Earnings date||1 Mar. 2016 - 5 Mar. 2016|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.08|
Sydney, Australia, Sep 8, 2017 - (ABN Newswire) - Boehringer Ingelheim and pharmaceutical research company Pharmaxis (ASX:PXS) (OTCMKTS:PXSLY) announce that Boehringer Ingelheim is initiating the Phase ...
Sydney, Australia, Sep 8, 2017 - (ABN Newswire) - Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX:PXS) (OTCMKTS:PXSLY) announce that Boehringer Ingelheim has initiated a European and North ...
INGELHEIM, Germany & SYDNEY--(BUSINESSWIRE)-- Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX:PXS.AX - News) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015. The compound is an oral inhibitor of amine oxidase, copper containing 3 (AOC3)1, and works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes underlying NASH. Non-alcoholic fatty liver disease (NAFLD), the most common liver disorder in Western industrialized nations, and its more serious form NASH, is highly prevalent amongst patients with type 2 Diabetes.